Author

Peter Eckmann

Stanford UniversityORCID 0000-0002-5388-9451Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 2 Organism:human· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:database / resource· 1 Research Focus:drug response / drug discovery· 1 Assay:electronic health records· 1 Approach:experimental assay· 1

Frequent Co-Authors

A.M. EdwardsiD· 1 shared Andrew B. MahoniD· 1 shared Anita E. BandrowskiiD· 1 shared Carl LaflammeiD· 1 shared Claire M. BrowniD· 1 shared Donovan WorralliD· 1 shared Harrison G. ZhangiD· 1 shared Harvinder S VirkiD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

A.M. EdwardsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Virtual Biotech: A Multi-Agent AI Framework for Therapeutic Discovery and Development

Harrison G. Zhang, Peter Eckmann, Jiacheng Miao, Andrew B. Mahon, James Zou

The Virtual Biotech uses AI agents to integrate multi-omic and clinical data for drug discovery, identifying genomic features linked to trial success and proposing therapeutic strategies.

Science · Sep 17, 2026Peer-reviewedGenomics

Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications

Riham Ayoubi, Joël Ryan, Michael Biddle, Walaa Alshafie, Maryam Fotouhi, Sara González Bolívar, Vera Ruíz Moleón, Peter Eckmann, Donovan Worrall, Ian McDowell, Kathleen Southern, Wolfgang Reintsch, Thomas M. Durcan, Claire M. Brown, Anita E. Bandrowski, , Carl Laflamme

Over half of 614 commercial antibodies for 65 human neuroscience proteins failed a knockout-controlled assay, yet most targets had a well-performing antibody; recombinants performed best.

eLife · Oct 5, 2023Peer-reviewedMolecular Biology✦ In-depth digest